ANI Pharmaceuticals (NASDAQ:ANIP) Hits New 52-Week Low – Should You Sell?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) hit a new 52-week low during trading on Monday . The stock traded as low as $52.37 and last traded at $52.37, with a volume of 1301 shares changing hands. The stock had previously closed at $55.04.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on ANIP shares. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Truist Financial boosted their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. Leerink Partners started coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target for the company. Raymond James upped their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $77.71.

ANI Pharmaceuticals Trading Up 0.4 %

The company has a 50 day moving average of $56.54 and a 200 day moving average of $58.96. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of -98.47 and a beta of 0.73. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company had revenue of $148.30 million during the quarter, compared to analysts’ expectations of $144.37 million. During the same period last year, the business earned $1.05 earnings per share. The business’s revenue was up 12.5% on a year-over-year basis. As a group, research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current year.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 7,500 shares of ANI Pharmaceuticals stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the transaction, the chief financial officer now owns 154,468 shares in the company, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the transaction, the senior vice president now directly owns 49,059 shares in the company, valued at $2,943,540. The trade was a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 42,381 shares of company stock worth $2,441,556 over the last ninety days. Corporate insiders own 12.70% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in ANI Pharmaceuticals by 24.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after purchasing an additional 579 shares in the last quarter. XTX Topco Ltd acquired a new stake in ANI Pharmaceuticals during the 2nd quarter valued at $207,000. Profund Advisors LLC acquired a new stake in ANI Pharmaceuticals during the 2nd quarter valued at $225,000. Susquehanna Fundamental Investments LLC acquired a new stake in ANI Pharmaceuticals during the 2nd quarter valued at $228,000. Finally, HighTower Advisors LLC acquired a new stake in ANI Pharmaceuticals during the 3rd quarter valued at $222,000. 76.05% of the stock is owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.